CMm, cáncer de mama metastásico; RH, receptor hormonal.
1. Slamon DJ,
et al. N Engl J Med
2001;
344
:783
792; 2. Marty M,
et al. J Clin Oncol
2005;
23
:4265
4274;
3. Kaufmann B,
et al. J Clin Oncol
2009, Johnston S, J Clin Oncol 2009;
4. Baselga J,
et al. N Engl J Med
2012;
366
:109–119;
5. Blackwell K,
et al. J Clin Oncol
2012;
30
:2585–2592.
1998
US approval:
HER-positive advanced BC1
2010
2000
2011
2013
2012
2007
Trastuzumab + anastrozol or Lapatinib + letrozol:
HER2+ ER+
Trastuzumab + lapatinib:
pretreated HER2+
5
Trastuzumab + pertuzumab
4
Evolution of treatment in HER2+ advanced
breast cancer
Approval in US
